SHANGHAI – At the Clinical Trials 9 event last week, it was clear the biopharma industry’s optimism has not been dented by the recent CFDA rejection of 1,200 applications – about 70 percent of its workload – for poor quality or fraudulent data. While one would think so many questionable drug applications would cast a pall on the industry, especially among clinical trial experts, that is not exactly the case.